Companies

Novartis/GSK – expensive restructuring?

GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.